J. Beck

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

P. Fasching, P. Neven, F. Esteva, 2019, The New England journal of medicine.

Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3.

P. Fasching, P. Neven, X. Pivot, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.